ArticleArchives of medical science : AMS2025

Cardiometabolic risk in non-diabetic metabolic dysfunction-associated steatotic liver disease (MAFLD) patients: insights from the triglyceride-glucose, plasma atherogenic, and cardiometabolic index.

Sedat Ciftel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.